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Introduction {#ehf212273-sec-0005}
============

Heart failure (HF) is a common disease, especially in elderly people, and is divided into two types based on cardiac systolic function: reduced ejection fraction (EF) and preserved EF.[1](#ehf212273-bib-0001){ref-type="ref"} It is recognized that a substantial proportion of HF patients have preserved EF (HFpEF), which has a similarly poor prognosis to HF with reduced EF (HFrEF).[2](#ehf212273-bib-0002){ref-type="ref"}, [3](#ehf212273-bib-0003){ref-type="ref"}

It is well known that the occurrence of HFpEF has been increasing year by year.[2](#ehf212273-bib-0002){ref-type="ref"} Crucial pathophysiological conditions in the development of HFpEF include prolonged isovolumic left ventricular (LV) relaxation, slow LV filling, increased diastolic LV stiffness, and LV diastolic dysfunction.[4](#ehf212273-bib-0004){ref-type="ref"}, [5](#ehf212273-bib-0005){ref-type="ref"}, [6](#ehf212273-bib-0006){ref-type="ref"} These pathophysiological characteristics are associated with increased ventricular--arterial stiffness and exaggerated blood pressure response to changes in ventricular loading in HFpEF patients.[7](#ehf212273-bib-0007){ref-type="ref"}, [8](#ehf212273-bib-0008){ref-type="ref"}, [9](#ehf212273-bib-0009){ref-type="ref"} In particular, in HFpEF patients, central aortic stiffness is increased, and arterial stiffness modulates ventricular loading conditions as well as LV diastolic function.[10](#ehf212273-bib-0010){ref-type="ref"}, [11](#ehf212273-bib-0011){ref-type="ref"}, [12](#ehf212273-bib-0012){ref-type="ref"} Aortic stiffness can be assessed by various non‐invasive methods, and aortic pulse wave velocity (PWV), which is one of the most frequently used parameters because it is easily measured, predicts future cardiovascular events, such as stroke and mortality.[13](#ehf212273-bib-0013){ref-type="ref"}, [14](#ehf212273-bib-0014){ref-type="ref"} PWV was commonly measured by carotid--femoral and brachial--ankle methods;[13](#ehf212273-bib-0013){ref-type="ref"} however, in recent years, it has become possible to self‐measure PWV using an ambulatory blood pressure monitoring device.[15](#ehf212273-bib-0015){ref-type="ref"}, [16](#ehf212273-bib-0016){ref-type="ref"}

Moreover, it is well known that sleep‐disordered breathing (SDB) has an adverse prognostic impact on HF patients, including not only HFrEF but also HFpEF patients.[17](#ehf212273-bib-0017){ref-type="ref"}, [18](#ehf212273-bib-0018){ref-type="ref"} Several studies have revealed higher PWV in obstructive sleep apnoea (OSA) patients than in controls and reported nocturnal oxygen desaturation to be associated with high PWV.[19](#ehf212273-bib-0019){ref-type="ref"}, [20](#ehf212273-bib-0020){ref-type="ref"}

Therefore, the purpose of the present study was to examine the relationship between PWV and SDB in HFpEF and HFrEF patients.

Methods {#ehf212273-sec-0006}
=======

Study subjects and protocol {#ehf212273-sec-0007}
---------------------------

This was a cross‐sectional study. We enrolled 221 consecutive HF patients who were hospitalized at Fukushima Medical University Hospital between March 2011 and April 2015 (mean age 64.5 years and 157 men). Symptomatic HF diagnosis was defined by well‐trained cardiologists using the Framingham criteria.[21](#ehf212273-bib-0021){ref-type="ref"} All HF cases were diagnosed on first admission by attending cardiologists. Patients with acute coronary syndrome and those who were receiving dialysis were excluded. We investigated the patients\' backgrounds, including age, gender, New York Heart Association (NYHA) functional class, vital signs on admission, co‐morbidities, laboratory data, and echocardiographic data during hospitalization. Plasma BNP concentrations were measured using a commercially available radioimmunoassay specific to human BNP (Shionoria BNP kit, Shionogi, Osaka, Japan). Estimated glomerular filtration rate was measured using the Modification of Diet in Renal Disease formula. These laboratory and investigation parameters were measured not in patients in an acute phase of HF, but in patients with stable HF immediately before discharge.

Echocardiography was blindly performed by an experienced echocardiographer using standard techniques. Two‐dimensional echocardiographic images were acquired from the parasternal long and short axes, apical long axis, and apical four‐chamber views. The following echocardiographic parameters were investigated: interventricular septum thickness, LV end‐diastolic diameter, LVEF, left atrial volume, early transmitral flow velocity to mitral annular velocity ratio (mitral valve E/e′), inferior vena cava diameter, tricuspid valve regurgitation pressure gradient (TR‐PG), and right ventricular fractional area change (RV‐FAC).[22](#ehf212273-bib-0022){ref-type="ref"} LVEF was calculated using a modified Simpson\'s method. We defined HFpEF as ≥50% of LVEF and HFrEF as \<50% of LVEF.

Written informed consent was obtained from all study subjects. Our study complies with the Declaration of Helsinki, and the study protocol was approved by the ethical committee of Fukushima Medical University.

Measurement of sleep state {#ehf212273-sec-0008}
--------------------------

All subjects underwent overnight full polysomnography (PSG) or were examined by portable recording Type III device with the use of standard techniques and scoring criteria for sleep stages and arousals from sleep as previously reported.[23](#ehf212273-bib-0023){ref-type="ref"}, [24](#ehf212273-bib-0024){ref-type="ref"} Briefly, PSG was performed using a computerized system (Alice 5, Philips Respironics, Murrysville, PA, USA) that monitored the patient\'s electroencephalogram, electrooculogram, submental electromyogram, electrocardiogram, and thoracoabdominal motion. Oronasal airflow and arterial oxyhaemoglobin saturation (SPO~2~) were monitored by an airflow pressure transducer and pulse oximetry, respectively. Some patients used a portable recording Type III device (LS‐300, FUKUDA DENSHI, Tokyo, Japan). Apnoea was defined as the absence of airflow for more than 10 s. Hypopnoea was defined as a \>30% reduction in monitored airflow accompanied by a decrease in SPO~2~ by \>3%. The major polysomnographic parameters investigated were the apnoea--hypopnoea index (AHI), central apnoea index, obstructive apnoea index, hypopnoea index, lowest SPO~2~, and mean SPO~2~. All HF patients were divided into three SDB groups according to AHI: none‐to‐mild SDB group (AHI \< 15 times/h, *n* = 77), moderate SDB group (15 \< AHI \< 30 times/h, *n* = 59), and severe SDB group (AHI \> 30 times/h, *n* = 85). We performed PSG on only inpatients with stable HF.

Measurement of pulse wave velocity {#ehf212273-sec-0009}
----------------------------------

Pulse wave velocity was estimated using a Mobil‐O‐Graph 24 h PWA Monitor (I.E.M. GmbH, Stolberg, Germany), which is the first automated self‐measurement ambulatory blood pressure monitoring device that uses brachial oscillometric blood pressure for a non‐invasive estimation of central blood pressure.[15](#ehf212273-bib-0015){ref-type="ref"}, [16](#ehf212273-bib-0016){ref-type="ref"} This device uses a novel transfer function‐like method (ARCSolver algorithm) with brachial cuff‐based waveform recordings, and its measurements of blood pressure, waveform, and PWV have been validated.[15](#ehf212273-bib-0015){ref-type="ref"}, [16](#ehf212273-bib-0016){ref-type="ref"}, [25](#ehf212273-bib-0025){ref-type="ref"}, [26](#ehf212273-bib-0026){ref-type="ref"} PWV measured by this device has a good correlation with that measured by traditionally used tonometry systems.[25](#ehf212273-bib-0025){ref-type="ref"}, [26](#ehf212273-bib-0026){ref-type="ref"} We evaluated PWV in patients with stable HF.

Statistical analysis {#ehf212273-sec-0010}
--------------------

Results are expressed as mean ± standard deviation in normally distributed data, and skewed variables are presented as median (interquartile range). Categorical variables are expressed as numbers and percentages, and *P* values of less than 0.05 were considered statistically significant. The baseline characteristics of the HFpEF patients were compared with those of the HFrEF patients using an unpaired Student\'s *t* test for continuous variables and a χ^2^ test for discrete variables. If data were not distributed normally, the Mann--Whitney U test was used for comparisons. To compare the three SDB groups, we used one‐way ANOVA followed by Tukey\'s post hoc test. Multivariable regression analysis was used to determine the variables that were significantly related to high PWV. We considered the following to be potential confounding factors that are known to affect PWV in HF patients: older age (65 years or older), gender, body mass index, presence of ischaemic heart disease, hypertension, diabetes, dyslipidaemia, chronic kidney disease, anaemia, and severe SDB. Parameters with statistical significance in the univariate analysis (*P* \< 0.05) were included in the multivariate analysis. Statistical analysis was performed using a standard statistical program package (SPSS Japan, Tokyo, Japan).

Results {#ehf212273-sec-0011}
=======

Of the study population, 70 patients were found to have HFpEF, and 151 were found to have HFrEF, and we compared baseline clinical characteristics (*Table* [1](#ehf212273-tbl-0001){ref-type="table-wrap"}). When compared with the HFrEF patients, the HFpEF patients were older (*P* = 0.004), and a larger proportion were female (*P* = 0.001). In addition, the HFpEF patients had higher body mass index (*P* = 0.045), less severe NYHA functional class (*P* = 0.005), higher systolic blood pressure (*P* = 0.019), lower prevalence of diabetes mellitus (*P* = 0.018), higher prevalence of atrial fibrillation (*P* = 0.027), and lower prevalence of ischaemic heart disease (*P* \< 0.001). Furthermore, PWV was higher (9.79 ± 2.05 vs. 8.73 ± 2.19 m/s, *P* = 0.001), renal function was better, and plasma BNP levels were lower in the HFpEF patients than in the HFrEF patients (*P* = 0.028 and *P* = 0.003, respectively). In echocardiographic data, the LV wall was thicker (*P* = 0.003) and the LV end‐diastolic diameter was smaller (*P* \< 0.001) in the HFpEF patients than in the HFrEF patients (*Table* [1](#ehf212273-tbl-0001){ref-type="table-wrap"}).

###### 

Comparisons of clinical characteristics between patients with heart failure with preserved ejection fraction and with reduced ejection fraction

                                                         HFpEF (*n* = 70)   HFrEF (*n* = 151)  *P* value
  ----------------------------------------------------- ------------------ ------------------- -----------
  Age (years)                                              68.2 ± 11.1         62.7 ± 13.7     0.004
  Gender (male/female)                                        39/31              118/33        0.001
  Body mass index (kg/m^2^)                                 25.1 ± 4.8         23.7 ± 4.8      0.045
  NYHA III and IV (*n*, %)                                   5 (7.1)            34 (22.5)      0.005
  Systolic BP (mmHg)                                       131.5 ± 36.2       120.0 ± 32.2     0.019
  Hypertension (*n*, %)                                     53 (75.7)          105 (69.5)      0.344
  Diabetes mellitus (*n*, %)                                22 (31.4)           73 (48.3)      0.018
  Dyslipidemia (*n*, %)                                     52 (74.3)          122 (80.8)      0.271
  Anaemia (*n*, %)                                          34 (48.6)           76 (50.3)      0.808
  CKD (*n*, %)                                              41 (58.6)          106 (70.2)      0.088
  IHD (n, %)                                                 8 (11.4)           54 (35.8)      \<0.001
  Pulse wave velocity (m/s)                                9.79 ± 2.05         8.73 ± 2.19     0.001
  Blood sample data                                                                            
  eGFR (mL/min/1.73 m^2^)                                  58.2 ± 17.9         50.8 ± 21.8     0.028
  BNP[a](#ehf212273-note-0002){ref-type="fn"} (pg/mL)     216.4 (334.9)       437.6 (714.4)    0.003
  hs‐CRP (mg/dL)                                           1.80 (0.51)         1.85 (0.78)     0.732
  Echocardiography                                                                             
  IVST (mm)                                                 12.6 ± 4.2         10.9 ± 2.9      0.003
  LVEDD (mm)                                                46.8 ± 9.4         58.8 ± 11.3     \<0.001
  LVEF (%)                                                  61.6 ± 8.8         38.3 ± 14.7     \<0.001
  E/e′                                                      14.7 ± 8.0         15.3 ± 9.2      0.693
  TR‐PG (mmHg)                                             31.7 ± 18.1         27.4 ± 11.8     0.087
  Diastolic RV area (mm^2^)                                 16.8 ± 7.4         18.8 ± 10.3     0.322
  RV‐FAC (%)                                               43.9 ± 18.5         40.7 ± 14.9     0.321

BNP, B‐type natriuretic peptide; BP, blood pressure; CKD, chronic kidney disease; E/e′, the ratio of early transmitral flow velocity to mitral annular velocity; eGFR, estimated glomerular filtration rate; HFpEF, heart failure with preserved ejection fraction; HFrEF, heart failure with reduced ejection fraction; hs‐CRP, high‐sensitivity C‐reactive protein; IHD, ischaemic heart disease; IVST, interventricular septum thickness; LVEDD, left ventricular end‐diastolic diameter; LVEF, left ventricular ejection fraction; NYHA, New York Heart Association classification; RV, right ventricular; RV‐FAC; right ventricular fractional area change; TR‐PG, tricuspid regurgitation pressure gradient.

Skewed data are reported as median (interquartile range).

In all subjects, 77 had none‐to‐mild SDB (34.8%), 59 had moderate SDB (26.7%), and 85 had severe SDB (38.5%). We compared baseline clinical characteristics among these SDB groups (*Table* [2](#ehf212273-tbl-0002){ref-type="table-wrap"}). Although age and body mass index correlated with SDB severity (*P* \< 0.001, respectively), no significant differences were observed in gender, NYHA functional class, vital signs, incidence of co‐morbidities, laboratory data, and echocardiographic data among the three groups. Sleep state analysis revealed that AHI, central apnoea index, obstructive apnoea index, hypopnoea index, lowest SPO~2~, and mean SPO~2~ worsened with increasing SDB severity. PWV was significantly higher in the severe SDB group than in the none‐to‐mild and moderate SDB groups (9.56 ± 2.38 vs. 8.33 ± 2.38 and 9.24 ± 1.67 m/s, *P* = 0.002).

###### 

Comparisons of clinical characteristics among three sleep‐disordered breathing groups

                                                            None to mild (*N* = 77)   Moderate (*N* = 59)   Severe (*N* = 85)  *P* value
  -------------------------------------------------------- ------------------------- --------------------- ------------------- -----------
  Age (years)                                                     60.2 ± 14.8             66.0 ± 11.0          67.3 ± 12.1     0.001
  Gender (male/female)                                               49/28                   44/15                64/21        0.206
  Body mass index (kg/m^2^)                                       22.9 ± 4.0              23.4 ± 3.9           25.8 ± 5.6      \<0.001
  NYHA III and IV (*n*, %)                                         13 (16.9)               12 (20.3)            14 (16.5)      0.816
  Systolic BP (mmHg)                                             120.5 ± 34.0            126.3 ± 36.4         124.8 ± 32.1     0.571
  Hypertension (*n*, %)                                            51 (66.2)               40 (67.8)            67 (78.8)      0.159
  Diabetes mellitus (*n*, %)                                       32 (41.6)               28 (47.5)            35 (41.2)      0.719
  Dyslipidaemia (*n*, %)                                           58 (75.3)               46 (78.0)            70 (82.4)      0.543
  Anaemia (*n*, %)                                                 42 (54.5)               32 (54.2)            36 (42.4)      0.218
  CKD (*n*, %)                                                     48 (62.3)               43 (72.9)            56 (65.9)      0.429
  IHD (*n*, %)                                                     23 (29.9)               15 (25.4)            24 (28.2)      0.848
  HFpEF/HFrEF                                                        26/51                   14/45                30/55        0.302
  Pulse wave velocity (m/s)                                       8.33 ± 2.38             9.24 ± 1.67          9.56 ± 2.38     0.002
  Blood sample data                                                                                                            
  eGFR (mL/min/1.73 m^2^)                                         53.0 ± 23.6             51.9 ± 19.2          53.7 ± 19.7     0.904
  BNP[a](#ehf212273-note-0004){ref-type="fn"} (pg/mL)            291.3 (487.6)           436.4 (652.4)        230.3 (494.9)    0.502
  hs‐CRP[a](#ehf212273-note-0004){ref-type="fn"} (mg/dL)          0.16 (0.34)             0.23 (1.57)          0.18 (0.42)     0.349
  Echocardiographic data                                                                                                       
  IVST (mm)                                                       12.0 ± 4.3              11.0 ± 2.8           11.2 ± 3.0      0.259
  LVEDD (mm)                                                      52.5 ± 12.0             55.5 ± 11.5          57.0 ± 12.3     0.087
  LVEF (%)                                                        44.8 ± 18.5             44.5 ± 16.9          46.4 ± 15.9     0.792
  E/e′                                                            15.9 ± 8.4              13.5 ± 6.6           15.6 ± 10.5     0.394
  TR‐PG (mmHg)                                                    27.7 ± 14.5             30.5 ± 13.8          28.6 ± 14.8     0.651
  Diastolic RV area (mm^2^)                                       17.5 ± 7.3              18.8 ± 14.3          18.3 ± 6.4      0.841
  RV‐FAC (%)                                                      45.0 ± 18.1             38.3 ± 15.3          41.3 ± 14.8     0.230
  Measurement of sleep state                                                                                                   
  AHI (/h)                                                         8.8 ± 3.8              22.6 ± 4.1           43.1 ± 12.4     \<0.001
  CAI (/h)                                                         0.9 ± 0.7               6.4 ± 5.9           12.9 ± 12.4     \<0.001
  OAI (/h)                                                         1.9 ± 1.7               3.4 ± 3.1            6.7 ± 6.3      \<0.001
  HI (h)                                                           6.1 ± 3.5              11.3 ± 6.8           17.6 ± 15.3     \<0.001
  Lowest SpO~2~ (%)                                               87.8 ± 5.7              81.4 ± 11.4          76.5 ± 10.6     \<0.001
  Mean SpO~2~ (%)                                                 96.8 ± 1.3              95.7 ± 2.2           94.2 ± 2.7      \<0.001

AHI, apnoea--hypopnoea index; BNP, B‐type natriuretic peptide; BP, blood pressure; CAI, central apnoea index; CKD, chronic kidney disease; E/e′, the ratio of early transmitral flow velocity to mitral annular velocity; eGFR, estimated glomerular filtration rate; HI, hypopnoea index; HFpEF, heart failure with preserved ejection fraction; HFrEF, heart failure with reduced ejection fraction; hs‐CRP, high‐sensitivity C‐reactive protein; IHD, ischaemic heart disease; IVST, interventricular septum thickness; LVEDD, left ventricular end‐diastolic diameter; LVEF, left ventricular ejection fraction; NYHA, New York Heart Association classification; OAI, obstructive apnoea index; RV, right ventricular; RV‐FAC; right ventricular fractional area change; SPO~2~, arterial oxyhaemoglobin saturation; TR‐PG, tricuspid regurgitation pressure gradient.

Skewed data are reported as median (interquartile range).

We analysed the HFpEF and HFrEF patients separately. Age and body mass index correlated with SDB severity in both the HFpEF and HFrEF patients, and male gender was significantly fewer in the none‐to‐mild SDB group than in the moderate and severe SDB groups in HFpEF patients (*P* = 0.023) ([*Tables S1* and *S2*](#ehf212273-supitem-0001){ref-type="supplementary-material"}). No significant differences were observed in vital signs, NYHA functional class, laboratory data, and echocardiographic data among the three SDB groups in both the HFpEF and HFrEF patients ([*Tables S1* and *S2*](#ehf212273-supitem-0001){ref-type="supplementary-material"}). PWV was significantly higher in the severe SDB group than in the none‐to‐mild and moderate SDB groups in the HFpEF patients (10.67 ± 1.88 vs. 8.77 ± 1.95 and 9.78 ± 1.80 m/s, *P* = 0.002) (*Figure* [*1*](#ehf212273-fig-0001){ref-type="fig"} *A*), but not in the HFrEF patients (8.96 ± 2.43 vs. 8.10 ± 2.56 and 9.08 ± 1.62 m/s, *P* = 0.068) (*Figure* [*1*](#ehf212273-fig-0001){ref-type="fig"} *B*).

![The comparisons of pulse wave velocity in (A) heart failure with preserved ejection fraction (HFpEF) and (B) heart failure with reduced ejection fraction (HFrEF). \#*P* \< 0.01 vs. the none‐to‐mild group; \**P* \< 0.05 vs. the moderate group.](EHF2-5-284-g001){#ehf212273-fig-0001}

The univariate and multivariate regression analyses to determine factors related to high PWV in the HFpEF and HFrEF patients are shown in *Table* [3](#ehf212273-tbl-0003){ref-type="table-wrap"}. Among considerable clinical risk variables such as age, gender, body mass index, ischaemic heart disease, presence of hypertension, diabetes, dyslipidaemia, chronic kidney disease, anaemia, and SDB, the presence of severe SDB was an independent predictor of high PWV in the HFpEF patients (β = 0.234, *P* = 0.005), but not in the HFrEF patients.

###### 

Multiple regression analysis to determine factors related to pulse wave velocity

                              Univariate   Multivariate            
  --------------------------- ------------ -------------- -------- ---------
  HFpEF patients                                                   
  Age (65 years or older)     0.714        \<0.001        0.549    \<0.001
  Gender (male)               0.100        0.409          ---      ---
  Body mass index (over 25)   −0.140       0.247          ---      ---
  Ischaemic heart disease     0.024        0.842          ---      ---
  Hypertension                0.487        \<0.001        0.247    0.006
  Diabetes mellitus           0.177        0.144          ---      ---
  Dyslipidaemia               −0.049       0.689          ---      ---
  CKD                         0.167        0.167          ---      ---
  Anaemia                     0.092        0.450          ---      ---
  Severe SDB                  0.377        0.001          0.234    0.005
  HFrEF patients                                                   
  Age (65 years or older)     0.697        \<0.001        0.648    \<0.001
  Gender (male)               −0.176       0.031          −0.089   0.152
  Body mass index (over 25)   −0.109       0.183          ---      ---
  Ischaemic heart disease     0.196        0.016          0.061    0.333
  Hypertension                0.180        0.027          0.114    0.063
  Diabetes mellitus           0.086        0.291          ---      ---
  Dyslipidaemia               0.051        0.535          ---      ---
  CKD                         0.256        0.001          0.044    0.479
  Anaemia                     0.205        0.012          0.010    0.876
  Severe SDB                  0.091        0.264          ---      ---

CKD, chronic kidney disease; HFpEF, heart failure with preserved ejection fraction; HFrEF, heart failure with reduced ejection fraction; SDB, sleep‐disordered breathing.

Next, we divided each SDB group into two subgroups: patients with central sleep apnoea (CSA)‐dominant sleep disorder and those with OSA‐dominant sleep disorder. Then we examined PWV in each subgroup. As shown in *Table* [4](#ehf212273-tbl-0004){ref-type="table-wrap"}, in HFpEF patients, PWV was significantly higher in the severe SDB group both with CSA and OSA than in the none‐to‐mild and moderate SDB groups (CSA: 10.25 ± 1.89 vs. 7.40 ± 1.46 and 9.98 ± 1.58 m/s, *P* = 0.011; OSA: 11.0 ± 1.86 vs. 9.54 ± 1.59 and 9.63 ± 2.05 m/s, *P* = 0.020), but not in HFrEF patients.

###### 

Comparisons of pulse wave velocity in heart failure with preserved ejection fraction and with reduced ejection fraction patients divided into central and obstructive sleep apnoea

                   None to mild   Moderate      Severe         *P* value
  ---------------- -------------- ------------- -------------- -----------
  HFpEF patients                                               
  CSA dominant     7.40 ± 1.46    9.98 ± 1.58   10.25 ± 1.89   0.011
  OSA dominant     9.54 ± 1.59    9.63 ± 2.05   11.00 ± 1.86   0.020
  HFrEF patients                                               
  CSA dominant     7.23 ± 1.98    8.84 ± 1.68   8.66 ± 2.71    0.076
  OSA dominant     8.48 ± 2.53    9.43 ± 1.48   9.37 ± 1.66    0.325

CSA, central sleep apnoea; HFpEF, heart failure with preserved ejection fraction; HFrEF, heart failure with reduced ejection fraction; OSA, obstructive sleep apnoea.

Discussion {#ehf212273-sec-0012}
==========

In the present study, we compared the relationship of arterial stiffness and SDB in HFpEF and HFrEF patients and revealed, with the use of a novel oscillometric PWV measurement device, that arterial stiffness increased according to SDB severity in HFpEF patients, but not in HFrEF patients. There was no inconsistency with previous report, which demonstrated that the plasma BNP level was significantly lower in the HFpEF patients than in the HFrEF patients.[27](#ehf212273-bib-0027){ref-type="ref"}

It is well known that LV diastolic dysfunction plays an essential pathophysiological role in the development of HFpEF. In HFpEF patients, LV diastolic relaxation abnormalities were revealed by pressure--volume analysis and echocardiographic examination.[7](#ehf212273-bib-0007){ref-type="ref"}, [8](#ehf212273-bib-0008){ref-type="ref"}, [28](#ehf212273-bib-0028){ref-type="ref"} Moreover, both ventricular stiffness and arterial stiffness increase with advancing age; further, ventricular--arterial stiffening, compliance, and relaxation abnormalities are common in patients with HFpEF.[7](#ehf212273-bib-0007){ref-type="ref"}, [10](#ehf212273-bib-0010){ref-type="ref"}, [11](#ehf212273-bib-0011){ref-type="ref"}, [12](#ehf212273-bib-0012){ref-type="ref"} In HFrEF patients, myocardial loss or degeneration and dysfunction play essential pathophysiological roles. A meta‐analysis revealed that low blood pressure and pulse pressure are related to prognosis in HFrEF patients.[29](#ehf212273-bib-0029){ref-type="ref"} Additionally, LV function is more affected by increased arterial stiffness in HFpEF than in HFrEF patients.

Aortic stiffness can be assessed by various non‐invasive methods such as augmentation index, cardio‐ankle vascular index, and PWV. Of these parameters, aortic PWV is one of the most frequently used because it is easily measured, and there are several reports about the association between HFpEF and PWV. A clinical study with a population of almost 2000 participants demonstrated that PWV was significantly correlated with echocardiographic E/A ratio and was higher in the study\'s diastolic HF group than in the non‐diastolic HF group.[30](#ehf212273-bib-0030){ref-type="ref"} Meta‐analysis including 26 studies with 6626 patients investigated the associations between diastolic dysfunction evaluated by echocardiography and arterial stiffness measured by brachial--ankle PWV (baPWV), carotid--femoral PWV, augmentation index, and cardio‐ankle vascular index. They concluded that baPWV showed significantly greater correlation with diastolic function compared with other tonometric techniques, and arterial stiffness measured by arterial tonometry and baPWV is an indicator of diastolic dysfunction.[31](#ehf212273-bib-0031){ref-type="ref"}

Moreover, arterial stiffness increases in OSA patients as severity of SDB increases, and nocturnal oxygen desaturation is associated with high PWV.[19](#ehf212273-bib-0019){ref-type="ref"}, [20](#ehf212273-bib-0020){ref-type="ref"}, [32](#ehf212273-bib-0032){ref-type="ref"}, [33](#ehf212273-bib-0033){ref-type="ref"} SDB including CSA and OSA occurs frequently in HF and has an adverse prognostic impact on HF patients.[17](#ehf212273-bib-0017){ref-type="ref"}, [18](#ehf212273-bib-0018){ref-type="ref"} In the current study, significantly higher PWV was observed in accordance with increased severity of SDB, including CSA and OSA, in the HFpEF patients, but not in HFrEF patients.

Furthermore, this research is significant in terms of the use of a new automated non‐invasive self‐measurement ambulatory blood pressure monitoring device to measure PWV. The Mobil‐O‐Graph 24 h PWA Monitor estimates brachial blood pressure using the oscillometric method,[15](#ehf212273-bib-0015){ref-type="ref"}, [16](#ehf212273-bib-0016){ref-type="ref"} and some studies have already reported the reliability of the device by showing good correlation with traditionally used tonometry PWV measurement systems.[24](#ehf212273-bib-0024){ref-type="ref"}, [25](#ehf212273-bib-0025){ref-type="ref"}

The prevalence of HFpEF has been continually increasing, and established useful pharmacotherapies in HFrEF patients have been ineffective in HFpEF patients.[34](#ehf212273-bib-0034){ref-type="ref"}, [35](#ehf212273-bib-0035){ref-type="ref"}, [36](#ehf212273-bib-0036){ref-type="ref"} Several studies have reported that continuous positive airway pressure therapy decreases blood pressure and PWV in SDB patients with hypertension in both the short‐term and long‐term.[37](#ehf212273-bib-0037){ref-type="ref"}, [38](#ehf212273-bib-0038){ref-type="ref"}, [39](#ehf212273-bib-0039){ref-type="ref"} Additionally, meta‐analysis has demonstrated that continuous positive airway pressure improves aortic stiffness in patients with OSA.[40](#ehf212273-bib-0040){ref-type="ref"} We previously reported that the reduction of all‐cause mortality in HFpEF patients with SDB after positive airway pressure treatment might be partly due to improvement of aortic stiffness.[41](#ehf212273-bib-0041){ref-type="ref"}, [42](#ehf212273-bib-0042){ref-type="ref"} Thus, it is possible to speculate that SDB management using positive airway pressure improves the prognosis of HFpEF patients via a decrease in arterial stiffness, which is one of the important mechanisms underlying HFpEF, as we reported in our previous study.

Study limitations {#ehf212273-sec-0013}
-----------------

The current study has several limitations. First, the sample size was small, and the study was conducted in a single centre. Second, HFpEF is common in patients with hypertension, diabetes, obesity, and/or renal dysfunction; however, in the current study, no significant difference was observed in the rate of hypertension between the HFpEF and HFrEF patients. One of the important reasons for this inconsistency may be the diagnostic criteria of hypertension, which was defined as an elevated systolic blood pressure of \>140 mmHg, a diastolic blood pressure of \>90 mmHg, or when patients had taken antihypertensive drugs. Some of the HFrEF patients had already taken angiotensin‐converting enzyme inhibitors or angiotensin receptor blockers or beta‐blockers for HF treatment. However, echocardiographic results revealed that the HFpEF patients had concentric hypertrophy (increased wall thickness and decreased LV end‐diastolic diameter); therefore, HFpEF patients were more influenced by hypertension compared with HFrEF patients. Third, the cut‐off line between HFpEF and HFrEF is controversial: 40% or 50%. The latest European Society of Cardiology guideline of HF categorizes EF into three groups: HFrEF (EF \< 40%), mid‐range EF (EF = 40--50%), and HFpEF (EF \> 50%).[43](#ehf212273-bib-0043){ref-type="ref"} We could not analyse our study subjects according to this classification due to the small sample size. Hence, large‐population and multicentre studies are needed. Moreover, this European Society of Cardiology guideline provides the newest diagnostic criteria of HF,[43](#ehf212273-bib-0043){ref-type="ref"} but we diagnosed HF using the Framingham criteria.[21](#ehf212273-bib-0021){ref-type="ref"}

Conclusions {#ehf212273-sec-0014}
===========

The current study demonstrated that severe SDB is associated with elevated atrial stiffness and may be related to the pathophysiology of HFpEF.
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**Table S1.** Comparisons of clinical characteristics in heart failure with preserved ejection fraction (HFpEF) patients among three SDB groups.

**Table S2.** Comparisons of clinical characteristics in heart failure with reduced ejection fraction (HFrEF) patients among three SDB groups.
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Click here for additional data file.
